Antizol

Antizol®

Fomepizole A proprietary injectable antidote for ethylene glycol–antifreeze poisoning. See Antifreeze.
References in periodicals archive ?
SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended Year Ended December 31, December 31, 2009 2008 2009 2008 Xyrem $31,644 $15,823 $96,763 $53,803 Luvox CR 5,675 3,057 18,345 5,728 Antizol and Antizol-Vet (1) - - - 5,106 Total $37,319 $18,880 $115,108 $64,637 (1) The Company sold its rights to and interests in Antizol and Antizol-Vet in August 2008.
The company, which focuses on treatments for niche psychiatric and neurological conditions, has several products on the market, including narcolepsy drug Xyrem (which is also in clinical trials for fibromyalgia) and Antizol, an antidote for ethylene glycol and methanol poisoning.
Antizol and Cystadane revenue for the quarter was $3.
SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2009 2008 2009 2008 Xyrem $22,362 $12,405 $40,081 $23,746 Luvox CR 4,116 714 7,716 714 Antizol and Antizol-Vet (1) - 1,632 - 4,275 Total $26,478 $14,751 $47,797 $28,735 (1) The Company sold its rights to and interests in Antizol and Antizol-Vet in August 2008.
SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended March 31, 2009 2008 Xyrem $17,719 $11,341 Luvox CR 3,600 - Antizol and Antizol-Vet (1) - 2,643 Total $21,319 $13,984 (1) The Company sold its rights to and interests in Antizol and Antizol-Vet in August 2008.
Xyrem prescribing grew well during the first quarter, especially in the second half of the quarter and sales of our antidote product Antizol were very strong.
SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended December Year Ended 31, December 31, 2008 2007 2008 2007 Xyrem $15,823 $11,120 $53,803 $39,018 Luvox CR 3,057 - 5,728 - Antizol (1) - 3,740 5,106 14,153 Cystadane (2) - - - 365 Total $18,880 $14,860 $64,637 $53,536 (1) The Company sold its rights to and interests in Antizol and Antizol- Vet in August 2008.
SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2008 2007 2008 2007 Xyrem $14,234 $9,646 $37,980 $27,898 Antizol 831 3,790 5,106 10,413 Luvox CR 1,957 - 2,671 - Cystadane - - - 365 Total $17,022 $13,436 $45,757 $38,676 JAZZ PHARMACEUTICALS, INC.
SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2008 2007 2008 2007 Xyrem $12,405 $9,628 $23,746 $18,252 Antizol 1,632 3,987 4,275 6,623 Luvox CR 714 - 714 - Cystadane - - - 365 Total $14,751 $13,615 $28,735 $25,240 JAZZ PHARMACEUTICALS, INC.
SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended March 31, 2008 2007 Xyrem $11,341 $8,624 Antizol 2,643 2,636 Cystadane - 365 Total $13,984 $11,625 JAZZ PHARMACEUTICALS, INC.
hospitals with emergency departments have purchased Antizol, an antidote for suspected or confirmed ethylene glycol or methanol poisoning.
SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended Year Ended December 31, December 31, 2007 2006 2007 2006 Xyrem $11,120 $8,082 $39,018 $29,049 Antizol 3,740 3,472 14,153 12,813 Cystadane (1) - 336 365 1,437 Total $14,860 $11,890 $53,536 $43,299 (1) Jazz Pharmaceuticals, Inc.